• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌转录组亚型。

Prostate Cancer Transcriptomic Subtypes.

机构信息

Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI, USA.

出版信息

Adv Exp Med Biol. 2019;1210:111-120. doi: 10.1007/978-3-030-32656-2_6.

DOI:10.1007/978-3-030-32656-2_6
PMID:31900907
Abstract

While the DNA of a tumor is often equated to a fingerprint or its unique genetic identify, a tumor's RNA profile represents a complex dynamic state more akin to a tumors personality or distinct behavior. Of the 11 types of RNA, the translational and clinical focus in prostate cancer has been primarily on mRNA and lncRNA. The most common use of RNA-based biomarkers is to assess a tumor's aggressiveness or treatment sensitivity. However, multiple gene expression signatures have been developed to capture the functional state that results from canonical DNA alterations, including ERG fusions, SPOP mutations, and Rb loss. More commonly, these biomarkers have been used to develop over 30 prognostic gene expression signatures, three of which are now commercially available and being increasingly incorporated into clinical trials. In parallel, the ability to use microarray and RNAseq technologies have allowed high throughput methods of performing whole transcriptomic analyses. This has enabled the discovery and training of numerous predictive biomarker signatures rooted in biologically informed pathways to determine which tumors are more sensitive or resistant to various treatments, including androgen-deprivation therapy, radiotherapy, chemotherapy, and PARP inhibition. This chapter will review the various types of RNA, technologies available to assess gene expression, and describe the available gene expression signatures for prostate cancer.

摘要

虽然肿瘤的 DNA 通常被等同于指纹或其独特的遗传标识,但肿瘤的 RNA 图谱代表了一种更类似于肿瘤个性或独特行为的复杂动态状态。在 11 种 RNA 中,前列腺癌的翻译和临床重点主要集中在 mRNA 和 lncRNA 上。基于 RNA 的生物标志物最常见的用途是评估肿瘤的侵袭性或治疗敏感性。然而,已经开发了多种基因表达特征来捕获源自规范 DNA 改变的功能状态,包括 ERG 融合、SPOP 突变和 Rb 缺失。更常见的是,这些生物标志物已被用于开发 30 多个预后基因表达特征,其中有 3 个现在可商业化,并越来越多地被纳入临床试验。与此同时,使用微阵列和 RNAseq 技术的能力允许进行高通量的全转录组分析。这使得能够发现和训练许多基于生物学信息途径的预测生物标志物特征,以确定哪些肿瘤对各种治疗方法(包括雄激素剥夺疗法、放疗、化疗和 PARP 抑制)更敏感或更耐药。本章将回顾各种类型的 RNA、评估基因表达的可用技术,并描述前列腺癌的现有基因表达特征。

相似文献

1
Prostate Cancer Transcriptomic Subtypes.前列腺癌转录组亚型。
Adv Exp Med Biol. 2019;1210:111-120. doi: 10.1007/978-3-030-32656-2_6.
2
Androgen deprivation modulates gene expression profile along prostate cancer progression.雄激素剥夺会随着前列腺癌的进展调节基因表达谱。
Hum Pathol. 2016 Oct;56:81-8. doi: 10.1016/j.humpath.2016.06.004. Epub 2016 Jun 21.
3
Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.基于全基因组数据的不断发展的转录组指纹作为前列腺癌的预后工具。
Biol Cell. 2015 Jul;107(7):232-44. doi: 10.1111/boc.201400097. Epub 2015 Jun 16.
4
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.SPOP 和 FOXA1 突变与 ERGwt 肿瘤中的 PSA 复发相关,而 SPOP 下调与 ERG 重排的前列腺癌相关。
Prostate. 2019 Jul;79(10):1156-1165. doi: 10.1002/pros.23830. Epub 2019 May 15.
5
Discovery of prostate cancer biomarkers by microarray gene expression profiling.通过基因表达谱微阵列发现前列腺癌生物标志物。
Expert Rev Mol Diagn. 2010 Jan;10(1):49-64. doi: 10.1586/erm.09.74.
6
The Proteogenomic Landscape of Curable Prostate Cancer.可治愈前列腺癌的蛋白质基因组全景分析
Cancer Cell. 2019 Mar 18;35(3):414-427.e6. doi: 10.1016/j.ccell.2019.02.005.
7
High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.TROP2的高表达表征了雄激素敏感和雄激素非依赖性前列腺癌细胞中的不同细胞亚群。
Oncotarget. 2016 Jul 12;7(28):44492-44504. doi: 10.18632/oncotarget.9876.
8
Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression.预后基因特征的趋同提示了人类前列腺癌进展的潜在机制。
Genes (Basel). 2020 Jul 16;11(7):802. doi: 10.3390/genes11070802.
9
Molecular signatures in breast cancer.乳腺癌的分子特征。
Methods. 2017 Dec 1;131:135-146. doi: 10.1016/j.ymeth.2017.06.032. Epub 2017 Jun 29.
10
Genome-wide gene expression analysis of prostate carcinoma.前列腺癌的全基因组基因表达分析
Semin Oncol. 2003 Oct;30(5):635-48. doi: 10.1016/s0093-7754(03)00349-x.

引用本文的文献

1
Machine learning based androgen receptor regulatory gene-related random forest survival model for precise treatment decision in prostate cancer.基于机器学习的雄激素受体调控基因相关随机森林生存模型用于前列腺癌的精准治疗决策
Heliyon. 2024 Sep 2;10(17):e37256. doi: 10.1016/j.heliyon.2024.e37256. eCollection 2024 Sep 15.
2
Niraparib restrains prostate cancer cell proliferation and metastasis and tumor growth in mice by regulating the lncRNA MEG3/miR-181-5p/GATA6 pathway.尼拉帕利通过调节长链非编码 RNA MEG3/miR-181-5p/GATA6 通路抑制前列腺癌细胞增殖、转移和肿瘤生长。
PeerJ. 2023 Nov 29;11:e16314. doi: 10.7717/peerj.16314. eCollection 2023.
3
Personalized 3-Gene Panel for Prostate Cancer Target Therapy.
用于前列腺癌靶向治疗的个性化三基因检测板
Curr Issues Mol Biol. 2022 Jan 15;44(1):360-382. doi: 10.3390/cimb44010027.
4
From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer.从组学到多组学方法深入分析前列腺癌的分子机制。
Int J Mol Sci. 2022 Jun 3;23(11):6281. doi: 10.3390/ijms23116281.
5
Salvage therapy for prostate cancer after radical prostatectomy.根治性前列腺切除术后的前列腺癌挽救治疗。
Nat Rev Urol. 2021 Nov;18(11):643-668. doi: 10.1038/s41585-021-00497-7. Epub 2021 Aug 6.
6
Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.前列腺上皮基因定义了治疗相关的前列腺癌分子亚型。
Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1080-1092. doi: 10.1038/s41391-021-00364-x. Epub 2021 Apr 26.